Journal
JOURNAL OF NEUROCHEMISTRY
Volume 136, Issue -, Pages 29-38Publisher
WILEY
DOI: 10.1111/jnc.13217
Keywords
IL-1 beta; inflammasome; neurodegenerative diseases
Categories
Funding
- National Multiple Sclerosis Society (NMSS) [RG-1785G9-2, CA-1068-A-10]
- NIH [R37-AI029564]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI029564] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The inflammasome is a large macromolecular complex that contains multiple copies of a receptor or sensor of pathogen-derived or damage-derived molecular patterns, pro-caspase-1, and an adaptor called ASC (apoptotic speck containing protein with a CARD), which results in caspase-1 maturation. Caspase-1 then mediates the release of pro-inflammatory cytokines such as IL-1 and IL-18. These cytokines play critical roles in mediating immune responses during inflammation and innate immunity. Broader studies of the inflammasome over the years have implicated their roles in the pathogenesis of a variety of inflammatory diseases. Recently, studies have shown that the inflammasome modulates neuroinflammatory cells and the initial stages of neuroinflammation. A secondary cascade of events associated with neuroinflammation (such as oxidative stress) has been shown to activate the inflammasome, making the inflammasome a promising therapeutic target in the modulation of neurodegenerative diseases. This review will focus on the pathogenic role that inflammasomes play in neurologic diseases such as Alzheimer's disease, traumatic brain injury, and multiple sclerosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available